AU2018250337B2 - Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds - Google Patents

Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds Download PDF

Info

Publication number
AU2018250337B2
AU2018250337B2 AU2018250337A AU2018250337A AU2018250337B2 AU 2018250337 B2 AU2018250337 B2 AU 2018250337B2 AU 2018250337 A AU2018250337 A AU 2018250337A AU 2018250337 A AU2018250337 A AU 2018250337A AU 2018250337 B2 AU2018250337 B2 AU 2018250337B2
Authority
AU
Australia
Prior art keywords
ibd
fucosyllactose
stool
ileum
rectum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018250337A
Other languages
English (en)
Other versions
AU2018250337A1 (en
Inventor
Lee A. Denson
Ardythe L. Morrow
David S. Newburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of AU2018250337A1 publication Critical patent/AU2018250337A1/en
Application granted granted Critical
Publication of AU2018250337B2 publication Critical patent/AU2018250337B2/en
Priority to AU2024203194A priority Critical patent/AU2024203194A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018250337A 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds Active AU2018250337B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203194A AU2024203194A1 (en) 2017-04-07 2024-05-14 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482840P 2017-04-07 2017-04-07
US62/482,840 2017-04-07
PCT/US2018/026631 WO2018187792A1 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203194A Division AU2024203194A1 (en) 2017-04-07 2024-05-14 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Publications (2)

Publication Number Publication Date
AU2018250337A1 AU2018250337A1 (en) 2019-10-24
AU2018250337B2 true AU2018250337B2 (en) 2024-02-15

Family

ID=63712677

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018250337A Active AU2018250337B2 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
AU2024203194A Abandoned AU2024203194A1 (en) 2017-04-07 2024-05-14 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203194A Abandoned AU2024203194A1 (en) 2017-04-07 2024-05-14 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Country Status (8)

Country Link
US (2) US20200129534A1 (https=)
EP (1) EP3606535A4 (https=)
JP (3) JP2020513014A (https=)
CN (1) CN110730665A (https=)
AU (2) AU2018250337B2 (https=)
BR (1) BR112019020911A2 (https=)
CA (1) CA3059265A1 (https=)
WO (1) WO2018187792A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021111422A1 (en) * 2019-12-06 2021-06-10 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain
CN111698994A (zh) 2017-11-30 2020-09-22 格礼卡姆股份公司 治疗小麦敏感性的hmo混合物
BE1027078A9 (nl) 2019-02-25 2020-09-28 Nutribam Bvba Samenstelling, voedingssupplement en werkwijze voor het ondersteunen en/of verbeteren van de darmgezondheid
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
EP4058031A4 (en) * 2019-11-14 2023-11-08 Glycom A/S SYNTHETIC COMPOSITION FOR BALANCING THE BALE ACID PROFILE IN THE INTESTINAL
CN111588726A (zh) * 2020-04-28 2020-08-28 南开大学 2′-岩藻糖基乳糖调节宿主肠道菌群及增强肠屏障的应用
CN116615203B (zh) * 2020-12-11 2025-03-07 帝斯曼知识产权资产管理有限公司 改进的益生元制剂
CN113486954B (zh) * 2021-07-06 2023-04-07 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
WO2023102071A1 (en) * 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
CN119842563B (zh) * 2025-03-17 2025-06-06 昆明医科大学第一附属医院(云南省皮肤病医院) 多尔氏菌emf18-06b1d及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202753A1 (en) * 2009-07-06 2012-08-09 Children's Hospital Medical Center D/B/A Cincinnati Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US20150265661A1 (en) * 2012-04-13 2015-09-24 Trustees Of Boston College Prebiotic effect of sialyllactose
WO2016066174A1 (en) * 2014-10-29 2016-05-06 Glycom A/S Synthetic composition and method for promoting mucosal healing
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009315A2 (en) * 2010-07-12 2012-01-19 The Regents Of The University Of California Bovine milk oligosaccharides
US20120020941A1 (en) * 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
JP6129821B2 (ja) * 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
EP2687845A1 (en) * 2012-07-20 2014-01-22 Nestec S.A. Fucose as a biomarker for gut immunity
AU2016208455A1 (en) * 2015-01-23 2017-06-15 Société des Produits Nestlé S.A. Nutritional composition useful in the treatment of IBD patients
EP3862002A1 (en) * 2015-01-26 2021-08-11 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202753A1 (en) * 2009-07-06 2012-08-09 Children's Hospital Medical Center D/B/A Cincinnati Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
US20150265661A1 (en) * 2012-04-13 2015-09-24 Trustees Of Boston College Prebiotic effect of sialyllactose
WO2016066174A1 (en) * 2014-10-29 2016-05-06 Glycom A/S Synthetic composition and method for promoting mucosal healing
WO2017046711A1 (en) * 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oliveira, V.R.B., et al., "Factors Associated with Low Intake of Dietary Fiber in Inflammatory Bowel Disease Patients". Health, 2014, no. 6, pages 1300-1309. *

Also Published As

Publication number Publication date
US20200129534A1 (en) 2020-04-30
CA3059265A1 (en) 2018-10-11
EP3606535A1 (en) 2020-02-12
US20220133758A1 (en) 2022-05-05
BR112019020911A2 (pt) 2020-05-12
JP2020513014A (ja) 2020-04-30
EP3606535A4 (en) 2020-12-16
AU2024203194A1 (en) 2024-05-30
WO2018187792A1 (en) 2018-10-11
JP2025041753A (ja) 2025-03-26
JP2023052629A (ja) 2023-04-11
AU2018250337A1 (en) 2019-10-24
CN110730665A (zh) 2020-01-24

Similar Documents

Publication Publication Date Title
AU2018250337B2 (en) Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
Belda et al. Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism
Caio et al. Nutritional treatment in Crohn’s disease
Tandon et al. A prospective randomized, double-blind, placebo-controlled, dose-response relationship study to investigate efficacy of f ructo-o ligo s accharides (FOS) on human gut microflora
Miele et al. Nutrition in pediatric inflammatory bowel disease: a position paper on behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition
Olendzki et al. An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report
Caenepeel et al. how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease
US9386793B2 (en) Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
Ashton et al. Early-onset paediatric inflammatory bowel disease
Ruigrok et al. The composition and metabolic potential of the human small intestinal microbiota within the context of inflammatory bowel disease
US10842811B2 (en) Inulin for preventing antibiotic resistant infection and pathogen colonization
Taguer et al. The complex interplay of diet, xenobiotics, and microbial metabolism in the gut: Implications for clinical outcomes
AU2017294806B2 (en) Use of resistant potato starch as a prebiotic to modify microbiota
WO2017000868A1 (zh) 一种组合包在制备用于改善和治疗人类小胖威利综合症的食品、药品、保健品、营养品中的应用
WO2016176484A1 (en) Use of oligosaccharide compositions to enhance weight gain
Singh et al. Dysbiosis—an etiological factor for cardiovascular diseases and the therapeutic benefits of gut microflora
Machida et al. Immunotherapy and microbiota for targeting of liver tumor-initiating stem-like cells
Bertin et al. Diet and gut microbiota in inflammatory bowel disease: a clinical and nutritional perspective
Liu et al. Gut microbiome and metabolome characteristics of patients with cholesterol gallstones suggest the preventive potential of prebiotics
BR122024023543A2 (pt) Composição farmacêutica, kit e usos de compostos 2'-fucosilactose no tratamento de doenças inflamatórias intestinais
Pinnelli et al. The Role Played by Imidazole Propionic Acid in Modulating Gut-Heart Axis and the Development of Atherosclerosis: An Explorative Review
Zhu et al. The changes of gut microbiota and metabolites in different drug-induced liver injuries
Haddadi et al. Signs, symptoms and complications of non-Hodgkin's lymphoma according to grade and stage in south Iran
Peters 7CHAPTER 7 Design of the VITA-GrAID study Studying potential effects of ileo-colonic delivered Vitamins or the Groningen Anti-Inflammatory Diet on the course of Crohn’s Disease and the microbiome of healthy
Limbergen et al. Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)